In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise…
Our journey began with a deep fascination for the intricate world of the human gut bacterial ecosystem and its profound impact on overall well-being. Our founders, a team of passionate researchers and healthcare professionals, were intrigued by the pivotal role this complex microbiota plays in maintaining human health. The various bacteria produce a a complex, yet synergistic, set of compounds in our intestines that exhibit profound wide-ranging effects on metabolism and immune function.
As we dove deeper into the science, we uncovered the potential of these biosynthetic molecules that mimic naturally occurring substances in addressing a variety of health challenges, from autoimmune disease to metabolic disorders. We were particularly captivated by how these simple organic compounds could influence complex cellular processes and serve as a communication bridge between our gut microbiome and immune system.
We discovered ways of increasing the selectivity and specificity of our biosynthetic compounds after elucidating pathways and targets. We have developed a platform technology that allows us to target specific diseases and create disease-specific drugs.
THE JOURNEY
Join us on this exciting journey as we work towards a healthier future, one molecule at a time.
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise…
JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ — SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory…
Ben Franklin Healthcare Investments Invests $1.3 Million in Four Companies Ben Franklin Healthcare Investments continues support of SFA Therapeutics with…
